Medicilon and BravoBio have reached a strategic collaboration on innovative vaccine IND R&D services

On June 28, 2022, Shanghai Medicilon Inc. (Medicilon) and Shanghai BravoBio Co. Ltd. (BravoBio) signed a strategic collaboration agreement online to officially become the collaboration partner.

In order to further advance the preclinical R&D process of innovative vaccines, BravoBio and Medicilon have reached a strategic collaboration.  According to the agreement, Medicilon will utilize the one-stop preclinical R&D service platform to provide BravoBio with R&D services including but not limited to drug discovery, pharmaceutical research and preclinical research, so that the BravoBio’s high-quality vaccines could enter the clinical trial stage faster than before.  In addition, both parties will give full play to their respective resource advantages to further deepen collaboration and achieve two-way empowerment.

Shanghai BravoBio Co., Ltd. (BravoBio) was established in Shanghai Zhangjiang Hi-Tech Park in March 2011, and moved to North Shanghai Biomedical Park in October 2021.  The subsidiary Wuhan BravoBio Co., Ltd. is a national high-tech enterprise and a member of China Association for Vaccine.  In 2020, BravoBio was named "China's Rising Star" by Deloitte and is the only vaccine company to win the award.  The company has gene editing/construction/cloning/detection, large-scale bacterial culture, large-scale cell/virus culture, preparation of biologically active substances (polysaccharides, proteins, viruses, etc.), chemical combination of polysaccharides and proteins, new adjuvants, new preparations, new esting and other advanced technology platforms to meet the needs of various innovative biomedicines, especially vaccine development.  BravoBio is committed to meeting the beautiful vision of healthy life for the people of China and the world, and is committed to becoming the main force in the field of global disease control through the development and market-oriented operation of blockbuster innovative vaccines.

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of 2021, Medicilon has provided new drug R&D services to more than 1,460 clients around the world, and participated in the R&D of 221 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.